Skip to main content

Consensi FDA Approval History

Last updated by Judith Stewart, BPharm on May 2, 2023.

FDA Approved: Yes (Discontinued) (First approved May 31, 2018)
Brand name: Consensi
Generic name: amlodipine and celecoxib
Dosage form: Tablets
Company: Purple Biotech Ltd.
Treatment for: High Blood Pressure, Osteoarthritis

Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis.

  • On February 9, 2022, Purple Biotech Ltd. announced in a press release that the agreement with the U.S distributor for Consensi had been terminated. It was concluded that commercialization of Consensi was not likely to generate significant revenue and achieve profitability in the near term, so in order to reduce expenses involved in maintaining the product, Consensi would be discontinued.
  • The marketing end date for Consensi was July 27, 2022.

Development timeline for Consensi

May 31, 2018Approval FDA Approves Consensi (amlodipine and celecoxib) for Treatment of Hypertension and Osteoarthritis Pain
Oct  2, 2017Kitov Announces Filing by FDA of New Drug Application for KIT-302
Jul 31, 2017Kitov Submits New Drug Application to FDA for KIT-302
Jun 26, 2017Kitov Updates on KIT-302 New Drug Application

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.